This educational activity is supported by an independent medical education grant from GSK.

Course Description

The era of antibody–drug conjugates (ADCs) in gynecologic oncology have shifted from promise to intense competition. In ovarian and endometrial cancers, platforms targeting FRα, HER2/HER3, TROP2, B7-H4, CDH6, and NaPi2b are advancing rapidly. Mirvetuximab soravtansine has improved outcomes for FRα-positive ovarian cancer, while trastuzumab deruxtecan has extended HER2-directed therapy to certain endometrial tumors. Next-generation ADCs are improving antigen selection, internalization, payload potency, and linker stability to address antigen heterogeneity, resistance, and class-specific toxicities highlighted in recent studies. This symposium will provide a clear, evidence-based overview of the ADC landscape. Faculty will differentiate competing designs, evaluate key and emerging trial data, and offer practical guidance on sequencing, toxicity management, and biomarker-driven patient selection. The program will also highlight active trials and company strategies shaping future standards of care, ensuring participants are prepared to incorporate ADC advances into practice with confidence and clarity.

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: Acrivon, AbbVie, AstraZeneca, Corcept Therapeutics, Eisai, Eli Lilly, Gilead, GSK, Karyopharm Therapeutics, Merck, Pfizer, Verastem

Participants will examine the mechanistic basis of whole-genome and exome-based personalized assay designs, alongside the latest clinical datasets validating their prognostic utility. Through interactive, case-based reviews, faculty will demonstrate how longitudinal ctDNA tracking helps clarify complex clinical scenarios, such as predicting first-line maintenance benefit, identifying platinum sensitivity, and ruling out pseudoprogression during immunotherapy. The presentation will also address critical barriers to integration, including analytical limits of detection, Clonal Hematopoiesis of Indeterminate Potential (CHIP) filtering, and guideline implementation.

To ensure a balanced perspective, this course contrasts ctDNA dynamics with traditional modalities, including CA-125 kinetics, investigative imaging cadence, and histopathological risk factors. Attendees will leave equipped to critically interpret molecular testing results and seamlessly integrate personalized genomic data into a multidisciplinary care framework.

Through cased-based learning, the program emphasizes the real-world application of molecular testing, including how to interpret biomarker results and integrate them into treatment.  Key trials such as SOLO-1, PAOLA-1, PRIMA, DUO-E and ARIEL3 will be discussed to illustrate evidence-based approaches to selecting the right therapy for the right patient, particularly in the context of PARP inhibitor use and HRD testing as well as target based ADCs.  The course acknowledges geographic disparities, particularly in areas with limited on-the-ground support and aims to provide practical guidance for clinicians who are working to implement testing and treatment strategies under local constraints.  Additionally, the program will explore emerging therapeutic targets and biomarkers, including the potential of antibody-drug conjugates (ADCs), Her2 and Folate Receptor Alpha, and discuss how evolving science is reshaping treatment landscapes. Consideration will be given to health equity, access to testing, and the implementation challenges faced by clinicians and patients across diverse care environments.

All content will be aligned with current regulatory guidelines and appropriate for independent medical education (IME), with a clear distinction between on-label use and emerging data requiring further validation.

Participants will receive an in-depth overview of the biological basis of ctDNA detection, the current clinical evidence supporting its utility, and its integration into clinical workflows. Case-based discussions will illustrate real-world applications, showcasing how ctDNA can optimize decisions on surveillance and therapeutic strategy. The program will also critically assess limitations and challenges of ctDNA-based MRD testing, including issues with sensitivity, false positives, access, and cost.

In alignment with a fair and balanced approach, the course will also explore other MRD detection modalities such as radiologic imaging, CA-125, and histopathology, highlighting comparative strengths and contexts for use. The program engages clinicians to learn how to interpret ctDNA MRD data and apply it effectively within a multidisciplinary care framework.

Through a detailed review of data from recent clinical trials and study designs, participants will gain critical insights into progression-free and overall survival (PFS/OS) subgroup analyses, including those based on MMR status, HRD, IO, P53 mutation profiles, and other biologically relevant subgroups. Special emphasis will be placed on interpreting unplanned analyses, understanding the impact of FDA approvals, and evaluating gaps in existing content that may hinder clinical decision-making.  This program will incorporate emerging and established treatment options to help clinicians differentiate within a complex and competitive therapeutic landscape. Discussion will also highlight unmet needs, where treatment guidance remains less clear.

This fair and balanced program includes expert-led dialogue on how evolving data—both planned and exploratory—should be interpreted in practice and how these findings might reshape frontline and recurrent treatment strategies in endometrial cancer.